Cochlear (COH) 주식 개요
코클리어는 전 세계 어린이와 성인을 위한 임플란트형 청각 솔루션을 제공합니다. 자세히 보기
COH Community Fair Values
Create NarrativeSee what 67 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$70
FV
39.3% 고평가 내재 할인율0.14%
Revenue growth p.a.
108
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
Cochlear Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | AU$97.53 |
| 52주 최고가 | AU$319.56 |
| 52주 최저가 | AU$88.74 |
| 베타 | 0.24 |
| 1개월 변동 | 2.66% |
| 3개월 변동 | -50.93% |
| 1년 변동 | -63.66% |
| 3년 변동 | -60.19% |
| 5년 변동 | -56.70% |
| IPO 이후 변동 | 3,206.10% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
새로운 내러티브 • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Recent updates
내러티브 업데이트 • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.새로운 내러티브 • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.내러티브 업데이트 • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.내러티브 업데이트 • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.내러티브 업데이트 • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.내러티브 업데이트 • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.
새로운 내러티브 • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.분석 기사 • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...분석 기사 • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
새로운 내러티브 • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?분석 기사 • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...내러티브 업데이트 • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.분석 기사 • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...분석 기사 • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...내러티브 업데이트 • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.분석 기사 • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...내러티브 업데이트 • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.분석 기사 • Jul 16
Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...분석 기사 • Jun 13
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • May 26
Why You Should Care About Cochlear's (ASX:COH) Strong Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...분석 기사 • Apr 05
Unpleasant Surprises Could Be In Store For Cochlear Limited's (ASX:COH) Shares
Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 46.1x might make it look like a strong sell right...분석 기사 • Mar 06
Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15
Cochlear Limited's ( ASX:COH ) dividend will be increasing from last year's payment of the same period to A$2.15 on...분석 기사 • Feb 23
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
새로운 내러티브 • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.분석 기사 • Feb 08
Is Cochlear Limited (ASX:COH) Worth AU$310 Based On Its Intrinsic Value?
Key Insights The projected fair value for Cochlear is AU$247 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Dec 20
Earnings Not Telling The Story For Cochlear Limited (ASX:COH)
Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 53x might make it look like a strong sell right...분석 기사 • Nov 19
Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...분석 기사 • Nov 04
Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights The projected fair value for Cochlear is AU$234 based on 2 Stage Free Cash Flow to Equity Cochlear's...분석 기사 • Oct 18
We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package
Key Insights Cochlear's Annual General Meeting to take place on 25th of October Total pay for CEO Dig Howitt includes...분석 기사 • Sep 19
Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 19x, you may consider...분석 기사 • Aug 16
Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Cochlear Limited ( ASX:COH ) shareholders are probably feeling a little disappointed, since its shares fell 5.4% to...분석 기사 • Aug 01
Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...분석 기사 • Jun 08
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • Mar 27
Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Feb 21
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Dec 18
Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...분석 기사 • Oct 04
Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights The projected fair value for Cochlear is AU$192 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Sep 12
Cochlear (ASX:COH) Could Be Struggling To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...주주 수익률
| COH | AU Medical Equipment | AU 시장 | |
|---|---|---|---|
| 7D | 1.2% | 1.8% | 0.08% |
| 1Y | -63.7% | -43.8% | 3.1% |
수익률 대 산업: COH은 지난 1년 동안 -43.8%의 수익을 기록한 Australian Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: COH은 지난 1년 동안 3.1%를 기록한 Australian 시장보다 저조한 성과를 냈습니다.
주가 변동성
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 10.4% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.4% |
안정적인 주가: COH는 지난 3개월 동안 Australian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: COH의 주간 변동성은 지난 1년간 7%에서 12%로 증가했지만 Australian 종목의 상위 75%보다 낮습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1981 | 5,500 | Dig Howitt | www.cochlear.com |
코클리어는 전 세계 어린이와 성인에게 이식형 청각 솔루션을 제공합니다. 이 회사는 인공와우 시스템, 사운드 프로세서 업그레이드, 골전도 시스템 및 기타 제품을 제공합니다. 또한 뉴클리어 사운드 프로세서, 스마트 바이모달 청각 솔루션, 뉴클리어 임플란트 등 뉴클리어 시스템, 바하 6 맥스 사운드 프로세서와 바하 임플란트로 구성된 바하 시스템, 무선 장치 및 뉴클리어 방수 액세서리 등 액세서리를 제공합니다.
Cochlear Limited 기초 지표 요약
| COH 기초 통계 | |
|---|---|
| 시가총액 | AU$6.38b |
| 순이익 (TTM) | AU$345.30m |
| 매출 (TTM) | AU$2.34b |
18.5x
주가수익비율(P/E)2.7x
주가매출비율(P/S)COH는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| COH 손익계산서 (TTM) | |
|---|---|
| 매출 | AU$2.34b |
| 매출원가 | AU$636.90m |
| 총이익 | AU$1.70b |
| 기타 비용 | AU$1.36b |
| 순이익 | AU$345.30m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Aug 18, 2026
| 주당순이익(EPS) | 5.28 |
| 총이익률 | 72.76% |
| 순이익률 | 14.77% |
| 부채/자본 비율 | 0.7% |
COH의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
4.4%
현재 배당 수익률81%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/23 13:52 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cochlear Limited는 26명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |